|
| AstraZeneca Partner Pozen Submits PN400 New Drug Application |
30 Jun 09, 13:08 |
|
| LONDON -(Dow Jones)- AstraZeneca PLC (AZN) said Tuesday its development partner, Pozen Inc (POZN), has submitted a new drug application, or NDA, to the U.S. Food and Drug Administration for VIMOVO (PN400) tablets, which if approved will trigger a $10 million milestone payment to Pozen. |
| more |
|
